SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 547.07 |
| Enterprise Value ($M) | 579.10 |
| Book Value ($M) | 267.70 |
| Book Value / Share | 1.98 |
| Price / Book | 2.04 |
| NCAV ($M) | -92.76 |
| NCAV / Share | -0.69 |
| Price / NCAV | -5.90 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.08 |
| Return on Assets (ROA) | -0.06 |
| Return on Equity (ROE) | -0.10 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.78 |
| Current Ratio | 0.78 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 176.18 |
| Assets | 536.65 |
| Liabilities | 268.94 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Tco Group Holdings, L.p. | 83.38 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,449 | 29,645 | 11.63 | |
| 3,776 | 41,535 | 9.09 | |
| 2,534 | 17,924 | 14.14 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| IMVT – Immunovant, Inc. | INBX – Inhibrx Biosciences, Inc. |
| INDV – Indivior PLC | INSM – Insmed Incorporated |
| INVA – Innoviva, Inc. |
Financial data and stock pages provided by
Fintel.io